Almirall completes $550m acquisition of five dermatology brands from Allergan
In a significant move within the pharmaceutical industry, Spanish pharmaceutical company Almirall has finalised its $550 million acquisition of five dermatology medications from Allergan’s Medical Dermatology unit in the United States. This strategic acquisition, first announced in August 2018, aims to expand Almirall’s footprint in the US dermatology market. Acquisition Details and Financial Implications The […]